Evaluation of the Intensity and Duration of the Bronchodilatory Action of Fenoterol – Ipratropium Bromide in Combination Compared with Terbutaline and Placebo in Patients with Chronic Obstructive Lung Disease

Longhini, E; Bozzoni, Marina; Mastropasqua, Berardino; Marazzini, L

doi:10.1159/000195120

Cited by 2 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The typical side effects of (l2-receptor agonists can be reduced substantially by using smaller doses [13,14]. The longer bronchodilating action of the combined IB/F is an additional advantage [15][16][17], However, it has not yet been shown convincingly whether all patients with COPD can profit from the effects of the combination F/IB. The aim of the present study was to assess both the bronchodilating effect and duration of the combination F/IB (Berodual®) in patients with COPD at the dosage of 2 puffs, each containing F 0.05 mg and IB 0.02 mg.…”

Section: Introductionmentioning

confidence: 99%

Comparison of Bronchodilator Effects of Fenoterol/lpratropium Bromide and Salbutamol in Patients with Chronic Obstructive Lung Disease

Imhof

Elsässer²,

Karrer³

et al. 1993

Respiration

View full text Add to dashboard Cite

A double-blind, randomized cross-over trial was carried out in 24 patients with chronic airflow obstruction. The patients were required to demonstrate a minimum 15% absolute increase in forced expiratory volume (FEV₁ after a standard dose (0.4 mg) of fenoterol (F). On a separate occasion the effect of ipratropium bromide (IB; 0.04 mg) on FEV₁ was tested also; according to the increase in FEV₁ the patients were grouped into IB responders (ΔFEV₁ 15%) and IB nonresponders (ΔFEV₁ < 15%). Two puffs of F/IB (0.1 mg/0.04 mg), salbutamol (S; 0.2 mg) and placebo (P) were given by metered-dose inhaler at the same time of the day on three different occasions. FEV₁ and specific airway resistance (sRaw) were assessed before and at specific intervals following inhalation. The results showed that F/IB and S produced similar maximal increases in FEV₁ (ΔFEV₁ 32% for F/IB and 31% for S) and decreases in sRaw (ΔsRaw 24% for F/IB and 21% for S). These effects were significantly different both from baseline values and from P. FEV₁ was still significantly different 8 h after inhalation from P in the F/IB group, but not in the group that received S. The effect of IB on FEV₁ in the pretest was compared with the subsequent response to F/IB. In IB responders F/IB seemed to produce slightly more effective bronchodilation. Side effects were minimal and clinically insignificant. In conclusion, F/IB, with its ability to effect sustained bronchodilation without adverse side effects, is a viable alternative to a monotherapy in chronic obstructive pulmonary disease.